Human Anti-PCSK9 Recombinant Antibody (clone 3D2) (CAT#: VS-0323-CJ36)

• Host Species
• Human

• Type
• Human IgG

• Specificity
• Human PCSK9

• Species Reactivity
• Human

• Clone
• 3D2

• Applications
• Western Blot, Enzyme-linked Immunosorbent Assay, Immunoassay, Inhibition, Blocking, Bio-layer Interferometry Analysis, Functional Assay

• Conjugate
• Unconjugated

• Related Disease
• Cardiovascular disease; Hypercholesterolemia

• Purity
• >95% as determined by SDS-PAGE

• Buffer
• PBS

• Storage
• Store at 4°C for short term. Aliquot and store at -20°C for long term. Avoid repeated freeze/thaw cycles.

• Application Notes
• ELISA: 5 nM-20 nM
  Western blot: 5 µg/mL-10 µg/mL
  Bio-layer interferometry analysis: 0.14 μg/mL-2.25 μg/mL

• Alternative Names
• FH3; PC9; FHCL3; NARC1; LDLCQ1; NARC-1; HCHOLA3

• Gene ID
• 255738

• UniProt ID
• Q8NBP7

• Sequence Similarities
• Belongs to the peptidase S8 family.

• Cellular Localization
• Cytoplasm; Endoplasmic reticulum; Endosome; Golgi apparatus; Lysosome; Secreted

• Post Translation Modifications
• Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation.
  Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein.
  Phosphorylation protects the propeptide against proteolysis.

• Protein Refseq
• NP_777596.2

• Function
• Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658).
  Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827).
  Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751).
  Inhibits epithelial Na+ channel (ENaC)-mediated Na+ absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Isotype Control

• MRO-A1587-YJ
• Human IgG Isotype control, Polyclonal

Secondary Antibody

• 2ND-024CQ
• Goat Anti-Human IgG (H&L) Antibody

• 2ND-025CQ
• Rabbit Anti-Human IgG (H&L) Antibody

Recommended Dilution Buffer

• MRO-0253YJ
• Reconstitution Buffer PBS

Select a product category from the dropdown menu below to view related products.